Revvity

RVTY · NYSE

$156.01+$5.07 (+3.36%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $150.94

Latest news

Press releaseOct 20, 8:00 AM ETBusiness Wire
Revvity Launches Signals LabGistics Solution to Connect and Orchestrate Scientific Workflows
Press releaseOct 13, 8:00 AM ETBusiness Wire
Revvity to Present at Upcoming Investor Conferences
NewsOct 6, 2:51 PM ETVandana Singh
Revvity Nears 52-Week High, but This Analyst Thinks Stock Can Climb Another 20%
Press releaseOct 6, 8:00 AM ETBusiness Wire
Revvity to Host Investor Day
Press releaseOct 2, 8:00 AM ETBusiness Wire
Revvity to Hold Earnings Call on November 3, 2026
NewsSep 25, 5:22 AM ET
Full Transcript: Revvity Q2 2026 Earnings Call
Press releaseSep 24, 8:00 AM ETBusiness Wire
Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes
NewsSep 18, 4:11 PM ETPiero Cingari
Fed Raises Rates, Yields Hit 2007 Highs as Fuel Costs Set Records: This Week On Wall Street
NewsSep 15, 1:27 PM ETPiero Cingari
10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today
NewsSep 9, 9:35 AM ETVandana Singh
Revvity Bets on GLP-1 Boom With Human Cell Design Acquisition
NewsSep 9, 6:09 AM ET
Revvity To Acquire French Biotech Firm Human Cell Design To Gain Exposure To Human Cell Models And Preclinical Research Solutions For Diabetes, Obesity And Other Metabolic Diseases
Press releaseSep 9, 6:00 AM ETBusiness Wire
Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery
NewsAug 4, 8:34 AM ET
Transcript: Revvity Q2 2026 Earnings Conference Call
NewsAug 4, 6:00 AM ET
Revvity Q2 Adj. EPS $1.41 Beats $1.22 Estimate, Sales $729.688M Beat $709.035M Estimate
Press releaseAug 4, 6:00 AM ETBusiness Wire
Revvity Announces Financial Results for the Second Quarter of 2026
Press releaseJul 31, 4:05 PM ETBusiness Wire
Revvity Board Declares Quarterly Dividend
Press releaseJul 20, 8:00 AM ETBusiness Wire
Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure
Press releaseJul 8, 8:00 AM ETBusiness Wire
Revvity to Hold Earnings Call on Tuesday, August 4, 2026
Press releaseJul 1, 8:00 AM ETBusiness Wire
Revvity Expands Signals AI Ecosystem Through Anthropic Claude Integration
Press releaseJun 22, 8:00 AM ETBusiness Wire
Revvity Launches Signals AI, a Native Agentic Framework for Accelerating Scientific R&D
Press releaseMay 5, 6:00 AM ETBusiness Wire
Revvity Announces Financial Results for the First Quarter of 2026
Press releaseApr 30, 4:05 PM ETBusiness Wire
Revvity Board Declares Quarterly Dividend
Press releaseApr 16, 8:00 AM ETBusiness Wire
Revvity to Present at Upcoming Investor Conferences
Press releaseApr 10, 8:00 AM ETBusiness Wire
Revvity to Hold Earnings Call on Tuesday, May 5, 2026
Press releaseApr 9, 8:00 AM ETBusiness Wire
Revvity Unveils its Signals BioDesign Offering to Advance Biologic Research Workflows
Press releaseFeb 17, 8:00 AM ETBusiness Wire
Revvity to Present at Upcoming Investor Conferences
Press releaseFeb 5, 8:00 AM ETBusiness Wire
Revvity Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations at SLAS2026
NewsFeb 3, 10:00 AM ET
Transcript: Q 2026 Earnings Conference Call
Press releaseFeb 2, 6:00 AM ETBusiness Wire
Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2025
NewsJan 30, 10:00 AM ET
A Look at Revvity's Upcoming Earnings Report
Press releaseJan 26, 4:05 PM ETBusiness Wire
Revvity Board Declares Quarterly Dividend
Press releaseJan 12, 4:15 PM ETBusiness Wire
Revvity to Hold Earnings Call on Monday, February 2, 2026; Provides Update on Financial Performance
Press releaseJan 9, 8:00 AM ETBusiness Wire
Revvity Collaborates with Lilly to Expand Access to AI Drug Discovery Models
Press releaseDec 18, 8:00 AM ETBusiness Wire
Revvity to Present at J.P. Morgan Healthcare Conference
Press releaseDec 16, 8:00 AM ETBusiness Wire
Revvity Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials Discovery
Press releaseNov 10, 7:45 AM ETBusiness Wire
Revvity to Acquire ACD/Labs to Expand its Signals Software Capabilities
Press releaseOct 27, 6:00 AM ETBusiness Wire
Revvity Announces Financial Results for the Third Quarter of 2025
Press releaseOct 2, 8:00 AM ETBusiness Wire
Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes
Press releaseSep 2, 8:00 AM ETBusiness Wire
Revvity Establishes In Vivo Imaging Center of Excellence in North Carolina
Press releaseJul 28, 6:00 AM ETBusiness Wire
Revvity Announces Financial Results for the Second Quarter of 2025

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Revvity Launches Signals LabGistics Solution to Connect and Orchestrate Scientific Workflows

Revvity to Present at Upcoming Investor Conferences

Revvity Nears 52-Week High, but This Analyst Thinks Stock Can Climb Another 20%

Revvity to Host Investor Day

Revvity to Hold Earnings Call on November 3, 2026

Full Transcript: Revvity Q2 2026 Earnings Call

Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes

Fed Raises Rates, Yields Hit 2007 Highs as Fuel Costs Set Records: This Week On Wall Street

10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today

Revvity Bets on GLP-1 Boom With Human Cell Design Acquisition

Revvity To Acquire French Biotech Firm Human Cell Design To Gain Exposure To Human Cell Models And Preclinical Research Solutions For Diabetes, Obesity And Other Metabolic Diseases

Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery

Transcript: Revvity Q2 2026 Earnings Conference Call

Revvity Q2 Adj. EPS $1.41 Beats $1.22 Estimate, Sales $729.688M Beat $709.035M Estimate

Revvity Announces Financial Results for the Second Quarter of 2026

Revvity Board Declares Quarterly Dividend

Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure

Revvity to Hold Earnings Call on Tuesday, August 4, 2026

Revvity Expands Signals AI Ecosystem Through Anthropic Claude Integration

Revvity Launches Signals AI, a Native Agentic Framework for Accelerating Scientific R&D

Revvity Announces Financial Results for the First Quarter of 2026

Revvity Board Declares Quarterly Dividend

Revvity to Present at Upcoming Investor Conferences

Revvity to Hold Earnings Call on Tuesday, May 5, 2026

Revvity Unveils its Signals BioDesign Offering to Advance Biologic Research Workflows

Revvity to Present at Upcoming Investor Conferences

Revvity Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations at SLAS2026

Transcript: Q 2026 Earnings Conference Call

Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2025

A Look at Revvity's Upcoming Earnings Report

Revvity Board Declares Quarterly Dividend

Revvity to Hold Earnings Call on Monday, February 2, 2026; Provides Update on Financial Performance

Revvity Collaborates with Lilly to Expand Access to AI Drug Discovery Models

Revvity to Present at J.P. Morgan Healthcare Conference

Revvity Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials Discovery

Revvity to Acquire ACD/Labs to Expand its Signals Software Capabilities

Revvity Announces Financial Results for the Third Quarter of 2025

Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes

Revvity Establishes In Vivo Imaging Center of Excellence in North Carolina

Revvity Announces Financial Results for the Second Quarter of 2025